Cargando…

The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers

PURPOSE: Deutetrabenazine is a deuterated form of tetrabenazine with a confirmed lower rate of CYP2D6 metabolism of the active metabolites, α- and β-HTBZ. In this study, we assessed the effect of paroxetine, a potent CYP2D6 inhibitor, on the pharmacokinetics and safety of deutetrabenazine and its me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schneider, F., Stamler, D., Bradbury, M. J., Loupe, P. S., Gordon, M. F., Rabinovich-Guilatt, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724172/ https://www.ncbi.nlm.nih.gov/pubmed/34491372 http://dx.doi.org/10.1007/s00228-021-03202-0

Ejemplares similares

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers
por: Schneider, Frank, et al.
Publicado: (2020)

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
por: Schneider, Frank, et al.
Publicado: (2020)

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis
por: Schneider, Frank, et al.
Publicado: (2022)

On crushing of deutetrabenazine tablets
por: Knebel, Helena, et al.
Publicado: (2021)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Deutetrabenazine in Tics Associated with Tourette Syndrome
por: Jankovic, Joseph, et al.
Publicado: (2016)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
por: Fernandez, Hubert H, et al.
Publicado: (2019)

Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
por: Claassen, Daniel O., et al.
Publicado: (2017)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial
por: Jankovic, Joseph, et al.
Publicado: (2021)

Safety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers
por: Pluta, Ryszard M., et al.
Publicado: (2011)

Evaluation of Pharmacokinetics and Safety with Bioequivalence of Ibuprofen Sustained-Release Capsules of Two Formulations, in Chinese Healthy Volunteers: Bioequivalence Study
por: Huang, Chunqi, et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers
por: Liu, Jian, et al.
Publicado: (2020)

Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial
por: Coffey, Barbara, et al.
Publicado: (2021)

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
por: Frank, Samuel, et al.
Publicado: (2022)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011)

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers
por: Han, Sungpil, et al.
Publicado: (2020)

Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study
por: Jankovic, Joseph, et al.
Publicado: (2023)

No major effects of vitamin D(3) (1,25 dihydroxyvitamin D(3)) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers
por: Kullak-Ublick, Gerd A., et al.
Publicado: (2016)

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study
por: Fernandez, Hubert H., et al.
Publicado: (2017)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants
por: Maden, Charlotte H., et al.
Publicado: (2018)

An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects
por: Round, Patrick, et al.
Publicado: (2011)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study
por: Mendzelevski, Boaz, et al.
Publicado: (2012)

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers
por: Fox, Gabriel M, et al.
Publicado: (2019)

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects
por: Boettcher, Michael, et al.
Publicado: (2020)

Benign Presentation Following Massive Deutetrabenazine Overdose
por: Obadeyi, Oluseyi, et al.
Publicado: (2021)

Case Report: Deutetrabenazine as an Adjunctive Treatment for Stuttering
por: Ha, Catherine A., et al.
Publicado: (2021)

TOPS: an internet-based system to prevent healthy subjects from over-volunteering for clinical trials
por: Boyce, M., et al.
Publicado: (2012)

Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022)

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers
por: Jung, Eben, et al.
Publicado: (2018)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020)

Amenamevir: Studies of Potential CYP2C8‐ and CYP2B6‐Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers
por: Dennison, Jeremy, et al.
Publicado: (2018)

Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers
por: Zimmermann, Torsten, et al.
Publicado: (2018)

2285: Analysis of racial disparity in the whole blood and plasma of healthy volunteers using rotational thromboelastometry
por: Janbain, Maissaa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lo06gouvup63aqd0ap92khubca